ZA984697B
(en)
*
|
1997-06-13 |
1999-12-01 |
Lilly Co Eli |
Stable insulin formulations.
|
US6211144B1
(en)
*
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
ES2329220T3
(es)
|
1999-01-06 |
2009-11-24 |
Genentech, Inc. |
Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
|
EP1141014B1
(de)
|
1999-01-06 |
2004-12-08 |
Genentech, Inc. |
Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
|
DE60005806T2
(de)
|
1999-04-08 |
2004-08-05 |
Genentech, Inc., South San Francisco |
Zusammensetzung auf basis gegensätzlich geladener polypeptide
|
US20040220103A1
(en)
*
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US6746853B1
(en)
|
1999-05-19 |
2004-06-08 |
Xencor, Inc. |
Proteins with insulin-like activity useful in the treatment of diabetes
|
US7169889B1
(en)
*
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
US7022674B2
(en)
*
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
AU2001220765A1
(en)
*
|
2000-01-24 |
2001-07-31 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
WO2001085256A2
(en)
*
|
2000-05-05 |
2001-11-15 |
Novo Nordisk A/S |
Critical illness neuropathy
|
EP1282437B1
(de)
|
2000-05-16 |
2008-03-19 |
Genentech, Inc. |
Behandlung von knorpelerkrankungen
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6852694B2
(en)
|
2001-02-21 |
2005-02-08 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
EP1412384B1
(de)
|
2001-06-28 |
2007-12-26 |
Novo Nordisk A/S |
Stabile formulierung von modifiziertem glp-1
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US20030068361A1
(en)
*
|
2001-10-09 |
2003-04-10 |
Rimona Margalit |
Liposome-encapsulated insulin formulations
|
US20030199445A1
(en)
*
|
2002-02-07 |
2003-10-23 |
Knudsen Lotte Bjerre |
Use of GLP-1 compound for treatment of critically ill patients
|
ATE496064T1
(de)
*
|
2002-05-07 |
2011-02-15 |
Novo Nordisk As |
Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
ITMI20021684A1
(it)
*
|
2002-07-29 |
2004-01-29 |
Therapicon Srl |
Composizione farmaceutica di peptide nasale
|
KR101123113B1
(ko)
*
|
2002-07-29 |
2012-03-15 |
쎄라피콘 에스.알.엘. |
코 펩티드 약학 제형
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004105790A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CA2910494C
(en)
|
2004-07-19 |
2018-10-23 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
WO2006020580A2
(en)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP5175103B2
(ja)
|
2004-11-12 |
2013-04-03 |
ノヴォ ノルディスク アー/エス |
安定なペプチド製剤
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
CA2593032C
(en)
|
2004-12-27 |
2015-12-22 |
Silence Therapeutics Ag |
Coated lipid complexes and their use
|
JPWO2006093222A1
(ja)
*
|
2005-03-02 |
2008-08-07 |
味の素株式会社 |
インスリンの多量体形成阻害剤
|
CN101180081B
(zh)
*
|
2005-05-25 |
2015-08-26 |
诺沃-诺迪斯克有限公司 |
稳定的多肽制剂
|
WO2006125762A1
(en)
*
|
2005-05-25 |
2006-11-30 |
Novo Nordisk A/S |
Stabilized polypeptide formulations
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CA2626357A1
(en)
*
|
2005-10-20 |
2007-04-26 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of rapid acting insulin
|
ES2371361T3
(es)
|
2005-12-28 |
2011-12-30 |
Novo Nordisk A/S |
Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
|
US8927015B2
(en)
*
|
2006-04-12 |
2015-01-06 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
CA2649630C
(en)
*
|
2006-04-20 |
2016-04-05 |
Silence Therapeutics Ag |
Lipoplex formulations for specific delivery to vascular endothelium
|
MX2008014024A
(es)
|
2006-05-04 |
2008-11-14 |
Boehringer Ingelheim Int |
Formas poliformas.
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
WO2007135117A2
(en)
*
|
2006-05-24 |
2007-11-29 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations
|
US9023793B2
(en)
*
|
2006-09-29 |
2015-05-05 |
Retrophin, Inc. |
Intranasal carbetocin formulations and methods for the treatment of autism
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
US8114428B2
(en)
*
|
2007-03-08 |
2012-02-14 |
Sbf Synthetic Bone Factory Gmbh |
Methods for manufacturing a composition for treating bone and/or cartilage defects
|
WO2008118387A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Wayne State University |
Erythrocyte atp-release modulators
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
MX2010003979A
(es)
*
|
2007-10-16 |
2010-06-02 |
Biocon Ltd |
Composicion farmaceutica oralmente administrable y proceso para su preparacion.
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
EP2910571B1
(de)
|
2008-03-18 |
2016-10-05 |
Novo Nordisk A/S |
Proteasestabilisierte, acylierte insulinanaloga
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
ES2519475T5
(es)
|
2008-05-01 |
2018-07-02 |
Arecor Limited |
Formulación de una proteína
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
EP2328607A1
(de)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stabile formulierung eines therapeutischen proteins
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
JP2012502048A
(ja)
|
2008-09-08 |
2012-01-26 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
US8650937B2
(en)
|
2008-09-19 |
2014-02-18 |
Tandem Diabetes Care, Inc. |
Solute concentration measurement device and related methods
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
ES2650621T3
(es)
|
2008-10-17 |
2018-01-19 |
Sanofi-Aventis Deutschland Gmbh |
Combinación de una insulina y un agonista de GLP-1
|
US8389522B2
(en)
|
2008-10-28 |
2013-03-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulators of aldehyde dehydrogenase and methods of use thereof
|
RU2540922C2
(ru)
|
2008-10-30 |
2015-02-10 |
Ново Нордиск А/С |
Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
|
CN107011345A
(zh)
|
2008-12-23 |
2017-08-04 |
勃林格殷格翰国际有限公司 |
有机化合物的盐形式
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
AU2010208381A1
(en)
|
2009-01-28 |
2011-08-04 |
Smartcells, Inc. |
Exogenously triggered controlled release materials and uses thereof
|
WO2010088286A1
(en)
|
2009-01-28 |
2010-08-05 |
Smartcells, Inc. |
Synthetic conjugates and uses thereof
|
PE20120582A1
(es)
|
2009-01-28 |
2012-05-26 |
Smartcells Inc |
Conjugados de insulina cristalina
|
SG173112A1
(en)
|
2009-01-28 |
2011-08-29 |
Smartcells Inc |
Conjugate based systems for controlled drug delivery
|
EP2397152B1
(de)
|
2009-02-12 |
2014-05-28 |
Proyecto de Biomedicina Cima, S.L. |
Verwendung von cardiotrophin-1 zur behandlung von stoffwechselerkrankungen
|
CA2753214C
(en)
|
2009-02-27 |
2017-07-25 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
US9250106B2
(en)
|
2009-02-27 |
2016-02-02 |
Tandem Diabetes Care, Inc. |
Methods and devices for determination of flow reservoir volume
|
WO2010107520A1
(en)
|
2009-03-20 |
2010-09-23 |
Smartcells, Inc. |
Soluble non-depot insulin conjugates and uses thereof
|
EP2408808A4
(de)
|
2009-03-20 |
2015-05-06 |
Smartcells Inc |
Terminal-funktionalisierte konjugate und ihre verwendung
|
WO2010149772A1
(en)
*
|
2009-06-26 |
2010-12-29 |
Novo Nordisk A/S |
Preparation comprising insulin, nicotinamide and an amino acid
|
EP2724739B1
(de)
|
2009-07-30 |
2015-07-01 |
Tandem Diabetes Care, Inc. |
Tragbares Infusionspumpensystem
|
PE20121362A1
(es)
|
2009-11-13 |
2012-10-17 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
|
TWI468171B
(zh)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
含glp-1激動劑及甲硫胺酸之醫藥組成物
|
EP3646859A1
(de)
|
2009-11-27 |
2020-05-06 |
Boehringer Ingelheim International GmbH |
Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin
|
CN101912600B
(zh)
*
|
2010-01-11 |
2014-01-29 |
杨国汉 |
改善胰岛素在溶液中稳定性的方法
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
BR112012032579B1
(pt)
|
2010-06-24 |
2021-05-11 |
Boehringer Ingelheim International Gmbh |
uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
|
CA2805739A1
(en)
|
2010-07-28 |
2012-02-02 |
Smartcells, Inc. |
Drug-ligand conjugates, synthesis thereof, and intermediates thereto
|
CA2806399A1
(en)
|
2010-07-28 |
2012-02-02 |
Smartcells, Inc. |
Recombinantly expressed insulin polypeptides and uses thereof
|
EP2598522A4
(de)
|
2010-07-28 |
2014-11-12 |
Smartcells Inc |
Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
BR112013010345A2
(pt)
|
2010-10-27 |
2017-07-25 |
Novo Nordisk As |
tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
CN102188367B
(zh)
*
|
2011-01-05 |
2012-11-07 |
山东新时代药业有限公司 |
一种甘精胰岛素注射液及其制备方法
|
US10457659B2
(en)
|
2011-04-29 |
2019-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for increasing proliferation of adult salivary stem cells
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130345113A1
(en)
*
|
2011-07-13 |
2013-12-26 |
Ronald E. Strohbehn |
Method of Use of Activated Functional Proteins to Improve Animal Health
|
HUE043540T2
(hu)
|
2011-07-15 |
2019-08-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
US9138479B2
(en)
*
|
2011-10-31 |
2015-09-22 |
Xeris Pharmaceuticals, Inc. |
Formulations for the treatment of diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP3685839A1
(de)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9555186B2
(en)
|
2012-06-05 |
2017-01-31 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
WO2014088836A1
(en)
|
2012-12-03 |
2014-06-12 |
Merck Sharp & Dohme Corp. |
O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
|
US9707275B2
(en)
*
|
2012-12-19 |
2017-07-18 |
Wockhardt Limited |
Stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
JP2016505601A
(ja)
*
|
2012-12-26 |
2016-02-25 |
ウォックハート リミテッド |
医薬組成物
|
TWI641381B
(zh)
*
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US10201656B2
(en)
|
2013-03-13 |
2019-02-12 |
Tandem Diabetes Care, Inc. |
Simplified insulin pump for type II diabetics
|
JP6410790B2
(ja)
|
2013-03-14 |
2018-10-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
US9492608B2
(en)
|
2013-03-15 |
2016-11-15 |
Tandem Diabetes Care, Inc. |
Method and device utilizing insulin delivery protocols
|
HUE042381T2
(hu)
|
2013-04-03 |
2019-06-28 |
Sanofi Sa |
Cukorbetegség kezelése hosszan ható inzulinkészítményekkel
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
WO2015008169A2
(en)
*
|
2013-07-04 |
2015-01-22 |
Insuline Medical Ltd. |
Device, system and method for delivery of a long-acting drug
|
WO2015051052A2
(en)
|
2013-10-04 |
2015-04-09 |
Merck Sharp & Dohme Corp. |
Glucose-responsive insulin conjugates
|
AR098168A1
(es)
|
2013-10-25 |
2016-05-04 |
Sanofi Sa |
Formulación estable de insulina glulisina
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
KR102351111B1
(ko)
*
|
2014-01-13 |
2022-01-14 |
써멀린 다이어비티즈, 엘엘씨 |
초속효성 인슐린 제형 및 약제학적 전달 시스템
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
RS64300B1
(sr)
|
2014-12-12 |
2023-07-31 |
Sanofi Aventis Deutschland |
Formulacija fiksnog odnosa insulin glargina/liksisenatida
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN105535942B
(zh)
*
|
2016-01-28 |
2017-07-28 |
通化东宝药业股份有限公司 |
一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
|
EP3419649A1
(de)
*
|
2016-02-25 |
2019-01-02 |
Wockhardt Limited |
Pharmazeutische zusammensetzung aus insulinglargin und aminosäuren
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
TWI700092B
(zh)
|
2016-12-16 |
2020-08-01 |
丹麥商諾佛.儂迪克股份有限公司 |
含胰島素醫藥組成物
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
PE20211202A1
(es)
|
2017-08-24 |
2021-07-05 |
Novo Nordisk As |
Composiciones de glp-1 y sus usos
|
US11820805B2
(en)
|
2017-12-18 |
2023-11-21 |
Merck Sharp & Dohme Llc |
Conjugate based systems for controlled insulin delivery
|
US11413352B2
(en)
|
2017-12-18 |
2022-08-16 |
Merck, Sharp & Dohme LLC |
Conjugate based systems for controlled insulin delivery
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
CN110063932A
(zh)
*
|
2019-04-12 |
2019-07-30 |
浙江大学 |
一种多肽蛋白类药物的缓释组合物制剂及其制备方法
|
PE20221575A1
(es)
|
2020-02-18 |
2022-10-06 |
Novo Nordisk As |
Formulaciones farmaceuticas
|
CA3173417A1
(en)
|
2020-03-31 |
2021-10-07 |
Alborz Mahdavi |
Conjugates for selective responsiveness to vicinal diols
|
WO2022109078A1
(en)
|
2020-11-19 |
2022-05-27 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and insulin analogs
|
WO2023017537A1
(en)
|
2021-08-12 |
2023-02-16 |
Celagenex Research (India) Pvt. Ltd. |
Oral algal oil based gastro-intestinal tract permeable peptide composition
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|